Research Article
Application of High-Efficiency Cell Expansion and High-Throughput Drug Sensitivity Screening for Leukemia Treatment
| Disease subtype | Characteristics | (range) | HEHDS | Non-HEHDS guided | values |
| AML | Patients | 121 | 79 | 42 | | Male/female | 57/64 | 35/44 | 22/20 | 0.397 | Median age | 48 | 46 | 50 | 0.238 | Median marrow blast % | 11.23% | 11.00% | 11.24% | 0.325 | Genetic anomaly at initial diagnosis | Normal karyotype without any molecular abnormality | 98 | 62 | 36 | 0.334 | FLT3-ITD | 23 | 17 | 6 | Disease status | New diagnosed | 43 | 26 | 17 | 0.408 | Relapsed | 78 | 53 | 25 |
| ALL | Patients | 27 | 17 | 10 | | Male/female | 13/14 | 7/10 | 6/4 | 0.345 | Median age | 37 | 35 | 39 | 0.195 | Median marrow blast % | 10.25% | 9.57% | 11.15% | 0.251 | Genetic anomaly at initial diagnosis | Normal karyotype without any molecular abnormality | 18 | 11 | 7 | 0.778 | BCR-ABL | 9 | 6 | 3 | Disease status | New diagnosed | 11 | 7 | 4 | 0.952 | Relapsed | 16 | 10 | 6 |
|
|